

NIH Public Access

Author Manuscript

Adv Synth Catal. Author manuscript; available in PMC 2010 July 23.

Published in final edited form as:

Adv Synth Catal. 2007 February 2; 349(3): 395-404. doi:10.1002/adsc.200600264.

Salicylaldimine Ruthenium Alkylidene Complexes: Metathesis Catalysts Tuned for Protic Solvents

Joseph B. Binder^a, Ilia A. Guzei^a, and Ronald T. Raines^{a,b,*}

^a Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, WI 53706-1322, USA

^b Department of Biochemistry, University of Wisconsin–Madison, 433 Babcock Drive, Madison, WI 53706-1544, USA

Abstract

Tuning the electronic and steric environment of olefin metathesis catalysts with specialized ligands can adapt them to broader applications, including metathesis in aqueous solvents. Bidentate salicylaldimine ligands are known to stabilize ruthenium alkylidene complexes, as well as allow ring-closing metathesis in protic media. Here, we report the synthesis and characterization of exceptionally robust olefin metathesis catalysts bearing both bidentate salicylaldimine and *N*-heterocyclic carbene ligands, including a trimethylammonium-functionalized complex adapted for polar solvents. NMR spectroscopy and X-ray crystallographic analysis confirm the structures of the complexes. Although the *N*-heterocyclic carbene–salicylaldimine ligand combination limits the activity of these catalysts in nonpolar solvents, this pairing enables efficient ring-closing metathesis of both dienes and enynes in methanol and methanol–water mixtures under air.

Keywords

N-heterocyclic carbenes; metathesis; ruthenium; Schiff bases; water; X-ray diffraction

Introduction

As an efficient, selective means for forming carbon–carbon bonds, olefin metathesis has revolutionized organic synthesis and polymer chemistry.[1] The high catalytic activity and functional group tolerance of well-defined ruthenium-based complexes **1–4a** allow extensive use of metathesis chemistry (Figure 1).[2–5] Still more diverse utilization of metathesis necessitates catalysts tailored to specific applications.[6] For instance, aqueous olefin metathesis is attractive for carbon–carbon bond formation in biological applications[7] and green chemistry,[8,9] yet complexes **1–4a** are insoluble in water and soluble versions such as **5** have proven to be unstable to air and incompatible with internal olefins.[10–12] Grubbs and coworkers have begun to address this challenge by modifying the local environment of the catalyst with a polyethylene glycol-bearing ligand, as in complex **4b**.[9] Here, our intent is to complement this approach by tuning the primary coordination sphere of the catalyst to the demands of aqueous media.

With the goal of creating designer catalysts for aqueous metathesis, we were attracted to reported ruthenium complexes containing bidentate salicylaldimine ligands, such as **6a–b**

Fax: (+1)-608-262-3453, raines@biochem.wisc.edu.

and **7a–b**.[13] These complexes display impressive stability and activity, and their readily accessible imine ligands lend themselves to catalyst tuning.[14] In addition, we were encouraged by the capacity of phosphine-bearing catalysts similar to **6a** to perform ringclosing metathesis (RCM) in methanol.[15] Aware of the benefits that N-heterocyclic carbene (NHC) ligands provide other ruthenium metathesis catalysts, we chose to investigate salicylaldimine complexes such as 7a and b reported by Verpoort and coworkers. [16-18] According to their work, this family of NHC-imine complexes efficiently catalyzes ring-opening metathesis polymerization (ROMP), RCM, and Kharasch addition. Iminebearing ruthenium complexes are proposed to enter the olefin metathesis catalytic cycle with decoordination of the imine nitrogen rather than the phosphine dissociation observed for initiation of 1 and 2.[14,17] As a result, we expected that an NHC ligand such as 1,3dimesityl-4,5-dihydroimidazol-2-ylidene (H₂IMes) could beneficially replace the spectator tricyclohexylphosphine of 6a-c, leading to improved thermal stability and enhanced olefin metathesis activity.[19,20] This report details our synthesis of NHC-imine metathesis catalysts and the first crystal structure of a member of this class, complex 7a, as well as the activity of water-adapted complex 7c.

Results and Discussion

Synthesis of NHC-Salicylaldimine Complexes

As shown in Scheme 1, our initial efforts concentrated on using the standard means for introducing the H₂IMes ligand, here, in situ formation of the free carbene from the imidazolinium salt with potassium tert-butoxide and subsequent reaction with the phosphine-bearing ruthenium complex 6a.[17] Attempts to prepare reported complex 7a by this published method resulted, however, in decomposition of the ruthenium benzylidene starting material. Faced with this roadblock, we chose to approach 7a-c by introducing salicylaldimine ligands to a complex already bearing the H₂IMes ligand. Alkoxide and aryloxide ligands, as well as neutral donors, react readily with bis(pyridine) precursor 8.[21] The chloride ligands in 8 are far more labile than in 2 and are displaced easily by incoming ligands, especially with the assistance of thallium ion. Accordingly, the thallium salts of salicylaldimine ligands 9a-c were prepared *in situ* with thallium ethoxide and reacted with 8 (Scheme 1). Gratifyingly, the green hexacoordinate starting material quickly formed winered complexes 7a-c as pyridine and chloride were displaced by the bidentate ligand. After the removal of thallium chloride and excess ligand, complexes 7a-c were isolated in good (56–87%) yield. Notably, this robust route even allowed access to cationic complex 7c with polar ligand 9c in DMF.

Manipulation of the NHC-imine complexes **7a–c** revealed their dramatic stability to air, heat, and water. These complexes tolerate storage for months as solids under vacuum without degradation as judged by ¹H NMR spectroscopy. Although **2** decomposes completely in less than 1 d in C₆D₆ at 55 °C under air, \geq 95% of complex **7b** is intact after 8 d according to ¹H NMR spectroscopy. Complex **7c** tolerates water, and remains <40% intact after 2 d in CD₃OD/D₂O (3:1) under air at 20 °C (according to integration of Ar–CH₃ and alkylidene ¹H NMR signals). In contrast, previous catalysts bearing ligands with cationic functional groups (such as **5** [12]) decompose in minutes when exposed to traces of oxygen in solution.

Interestingly, no exchange of the alkylidene proton of complex **7c** with solvent deuterons is observed in CD_3OD/D_2O (3:1). Such H/D exchange is observed for ruthenium alkylidene and vinylidene complexes without NHC ligands, including **5** and **6a**–**b**,[23] but not for complex **4b**.[9] Ligand electronics are known to affect the rate of alkylidene H/D exchange, [23] and the presence of the NHC ligands could slow this process.

Spectral and Structural Characterization of NHC–Salicylaldimine Complexes

¹H and ¹³C NMR spectral data for complexes **7a–b** synthesized by the route in Scheme 1 were consistent with their putative structures, but surprisingly did not match those previously reported for these complexes.[17] As listed in Table 1, the benzylidene proton resonance appears at δ 18.56 for **7a** while the literature reports δ 19.42, which is nearly the same as that reported for the parent phosphine-bearing complex **6a**.[14] Evidenced by ¹H and ¹³C NMR spectra of **1–4a**, replacement of the tricyclohexylphosphine ligand with H₂IMes typically results in a shielding effect on the alkylidene proton that shifts its resonance approximately 0.9 ppm upfield.[2–5] In addition, the observed ¹H spectrum of **7a** includes eight distinct Ar–CH₃ singlets, consistent with the asymmetry of the putative structure, while the literature spectrum reveals only six Ar–CH₃ resonances, including an aliphatic three-proton doublet. No coalescence of the methyl resonances of **7a** was observed at elevated temperature (55 °C in CDCl₃ or 70 °C in C₆D₆). Spectra for **7b–c** agree with these findings, with both complexes displaying benzylidene proton resonances about 0.9 ppm upfield from those of the parent complexes[24,15] and eight distinct methyl resonances.

To resolve this conflict, we sought crystallographic evidence. Suitable crystals of complex **7a** were grown by slow diffusion of pentane into a concentrated benzene solution over a few days. The crystalline material both displayed a ¹H NMR spectrum that was indistinguishable from that of complex **7a** prior to crystallization and retained RCM activity (*vide infra*). The X-ray data confirmed the structure of **7a**, as shown in Figure 2 (see the Supporting Information for additional details). Both **7a** and phosphine-bearing complexes similar to **6a**-**b** adopt a distorted trigonal-bipyramidal geometry; the common bond lengths and angles in the two classes of complex are virtually identical.[15] As in the phosphine-bearing complexes, the anionic moieties are *trans* with an O–Ru–Cl bond angle of 172.5° in NHC–imine complex **7a**. Just as in oxygen-ligated complex **4a**,[5] the Ru–C16 bond is shorter than that in complex **2** (2.085 Å),[25] possibly reflecting the lesser *trans* influence of the imine ligand relative that of a phosphine.[26]

Synthesis of Authentic 7a by Phosphine Displacement with H₂IMes

Returning to the original synthesis of complex **7a**, we sought to reproduce the published results by using the improved method for introducing the H₂IMes ligand reported by Nolan and coworkers.[27] Switching the reaction solvent to hexanes and the base to the more soluble potassium *tert*-amylate enhanced the synthesis, enabling the clean conversion of **6a** to **7a** as confirmed by ¹H NMR. Once again, spectral characterization failed to reveal the signals of the proposed imine complex reported by De Clercq & Verpoort,[17] Although these results confirm that **7a** is the authentic product of both our synthesis from H₂IMes complex **8** and the preparation from **6a**, the identity of the product reported previously[17] still remains unclear.

After we submitted this manuscript, Verpoort and coworkers reported the synthesis of complex **7b** and three similar NHC–imine complexes by a route similar to ours.[28] These workers found the RCM activity of their NHC–imine complexes in nonpolar solvents to be similar to that of the NHC–imine complexes reported herein (*vide infra*). Although they confirmed the structure of these complexes by X-ray crystallographic analysis, they did not comment on the discrepancies with their earlier paper[17] nor did they examine RCM catalysis in an aqueous environment.

Ring-Closing Metathesis Activity of 7a-c

Having confirmed the structure of the NHC–imine complexes, we investigated their activity for diene RCM. In contrast to previous reports,[16] complexes **7a–c** are dramatically less

active in nonpolar solvents (*e.g.*, benzene and CH_2Cl_2) than their phosphine-bearing counterpart, **6a** (Table 2). Elevated temperatures are necessary for metathesis. Even at 55 °C, complexes **7a** and **7b** require 40–72 h to achieve a high conversion of most substrates in toluene or benzene, but standard complexes **2**, **4a**, and **4c** and phosphine-bearing complexes such as **6a** achieve such transformations in a few hours or less.[14,15] Cationic complex **7c** shows similarly low activity in benzene, requiring 40 h for high conversions.

Yet, under similar conditions in methanol, complexes 7b and 7c catalyze the complete ringclosing of both polar and nonpolar substrates to form five-, six-, and seven-membered cyclic products in only 6-12 h. Although complex **7b** is less soluble in methanol than complex **7c**, these two catalysts display similar activity, demonstrating that the trimethylammonium substituent influences solubility more than reactivity. Unlike other metathesis catalysts adapted to protic solvents, complex 7c does not require inert atmosphere conditions for catalysis of RCM. In addition, complex 7c is effective for RCM of N,N-dimethyl-N,Ndiallylammonium chloride (10e), which has proven to be recalcitrant for other catalysts. [29,30] This specialized catalyst is also active in methanol–water mixtures, with 10 mol% of 7c achieving the highest conversion of N,N-diallylamine hydrochloride (10d) to RCM product 11d yet reported in an aqueous environment.[9,11,30-32] Moreover, 7c accomplishes this transformation cleanly. For comparison, Grubbs and coworkers reported 67% ring-closing of 10d along with 28% conversion to cycloisomer 12d using 5 mol% of complex 4b in water at room temperature over 36 h.[9] With a variety of nonpolar dienes 7c also achieves good to excellent conversions to five-, six-, and seven-membered rings in methanol-water mixtures. In contrast to RCM with complexes 7a-c in nonpolar solvents or methanol, RCM in the aqueous environment is limited by decomposition of the catalyst or intermediates-in the former solvents the intact complex is observable by NMR spectroscopy throughout the timecourse of the reaction, but in methanol-water the resonances of the complex disappear.

Enyne metathesis by salicylaldimine alkylidene ruthenium complexes has not been reported previously. We found that complexes **7a–c** are efficient catalysts of enyne RCM. Substrate **10k** is smoothly transformed in nonpolar solvents (5–36 h) and in protic media (2–6 h). For comparison, Grela and coworkers recently reported metathesis of **10k** with complex **4d** in 92% conversion in an aqueous solvent.[33] With **7a–c**, the more difficult substrate **10j** also undergoes ring closure to a moderate extent.

The solvent dependence of ring-closing metathesis with the NHC-imine complexes offers an explanation for their low activity. Catalysts bearing the H₂IMes ligand are typically more active in aromatic solvent than in CH_2Cl_2 .[34] In contrast, complex 7b is more active in more polar solvents (Table 3). This solvent dependence is consistent with the initiation rate trend for catalysis by 2, wherein switching from toluene to CH₂Cl₂ increased the initiation rate by 30%.[20] Together, these data suggest that the activity of NHC-imine complexes 7a-c is limited by their rate of initiation. Direct observations of metathesis reaction mixtures by ¹H NMR also support this conclusion. For both NHC-imine catalysts and several other chelated catalysts, [35] propagating alkylidene species are not detected during metathesis, and, in nonpolar solvents, the ¹H NMR signals for the complexes are typically unchanged upon completion. These results imply that the ligand combination in 7a-c allows only a small fraction of the complex species to participate in metathesis. Although NHC ligands improve metathesis propagation activities for ruthenium complexes, they tend to decrease their initiation rates drastically.[20] Switching from a tricyclohexylphosphine spectator ligand to an NHC could likewise decrease the initiation rate for imine complexes, such that they remain largely dormant as 16-electron species.[20] Increasing the temperature and solvent polarity apparently enables the complexes to surmount this hurdle, resulting in the high RCM activity of **7b**-c in a polar solvent. Thus, ruthenium NHC-imine complexes are

rare examples of complexes that are more active as metathesis catalysts in methanol than in nonpolar solvents.[31]

These characteristics of high stability and slow initiation suit salicylaldimine-based catalysts to specific applications. For example, complexes **7b–c** could enable ROMP in protic media, though their slow initiation rates are likely to result in large polydispersities that could be inappropriate for some applications.[36] Similarly, the low concentrations of propagating alkylidene species produced by salicylaldimine catalysts prevent them from supporting cross-metathesis. Nonetheless, these same qualities make NHC–salicylaldimine catalysts promising for RCM in aqueous environments. Slow initiation appears to protect the complex from water while providing a steady supply of active species with which to accomplish RCM. These advantages could be combined with the protective local environment provided by polyethylene glycol-functionalized ligands[9] to provide even more efficient catalysts for aqueous RCM.

Conclusion

Specialized ligands can tune the characteristics of olefin metathesis catalysts, adapting them to demanding applications, including metathesis in aqueous environments. We prepared ruthenium complexes bearing both NHC and salicylaldimine ligands, and confirmed their structure by NMR spectroscopy and X-ray crystallographic analysis. These new complexes initiate slowly, but are highly effective catalysts for diene and enyne RCM in protic media. The enhanced stability engendered by the salicylaldimine ligands allows trimethylammonium-functionalized complex **7c** to achieve clean RCM of *N*,*N*-diallylamine hydrochloride (**10d**) with the highest conversion yet reported in an aqueous environment. Further investigations will address the potential of these catalysts for RCM of more complex substrates as well as the possible enhancement of salicylaldimine-based catalysts with polyethylene glycol-bearing ligands.

Experimental Section

General Considerations

Commercial chemicals were of reagent grade or better, and were used without further purification. Anhydrous THF, DMF, and CH₂Cl₂ were obtained from CYCLE-TAINER[®] solvent delivery systems (J.T. Baker, Phillipsburg, NJ). Other anhydrous solvents were obtained in septum-sealed bottles. In all reactions involving anhydrous solvents, glassware was either oven-or flame-dried. Manipulation of organometallic compounds was performed using standard Schlenk techniques under an atmosphere of dry Ar(g), except as noted otherwise.

The term "concentrated under reduced pressure" refers to the removal of solvents and other volatile materials using a rotary evaporator at water aspirator pressure (<20 torr) while maintaining the water-bath temperature below 40 °C. In other cases, solvent was removed from samples at high vacuum (<0.1 torr). The term "high vacuum" refers to vacuum achieved by a mechanical belt-drive oil pump.

NMR spectra were acquired with a Bruker DMX-400 Avance spectrometer (¹H, 400 MHz; ¹³C, 100.6 MHz), Bruker Avance DMX-500 spectrometer (¹H, 500 MHz; ¹³C, 125.7 MHz), or Bruker Avance DMX-600 spectrometer (¹H, 600 MHz) at the National Magnetic Resonance Facility at Madison (NMRFAM). NMR spectra were obtained at ambient temperature unless indicated otherwise. Coupling constants *J* are given in Hertz.

Mass spectrometry was performed with a Micromass LCT (electrospray ionization, ESI) in the Mass Spectrometry Facility in the Department of Chemistry. Elemental analyses were performed at Midwest Microlabs (Indianapolis, IN).

N-(4-Bromo-2,6-dimethylphenyl)-salicylaldimine (**9a**), N-(4-bromo-2,6-dimethylphenyl)-5nitrosalicylaldimine (**9b**), and ruthenium imine complex **6a** were prepared according to the methods of De Clercq & Verpoort.[14] (3-Formyl-4-hydroxyphenyl)-trimethylammonium iodide was prepared according to the method of Ando & Emoto[37] and converted to the chloride salt by anion exchange. (H₂IMes)(C₅H₅N)₂(Cl)₂Ru=CHPh (**8**) was synthesized by the method of Grubbs and coworkers.[21]

The following RCM substrates were obtained from commercial sources and used without further purification: diethyl diallylmalonate (**10a**), *N*,*N*-diallyl-2,2,2-trifluoroacetamide (**10b**), allyl ether (**10f**), and 1,7-octadiene (**10h**) from Aldrich (Milwaukee, WI); *N*,*N*-diallyl-*N*,*N*-dimethylammonium chloride (**10e**) from Fluka (Buchs, Switzerland); and diallyldiphenylsilane (**10g**) from Acros Organics (Geel, Belgium).

N,*N*-Diallyl-4-methylbenzenesulfonamide (**10c**) was prepared by the method of Lamaty and coworkers.[38] Diallylamine hydrochloride (**10d**) was prepared from the corresponding amine (Aldrich) by treatment with ethereal HCl. *N*-(2-Propenyl)-4- methylbenzenesulfonamide was prepared by the method of Pagenkopf and coworkers.[39]

Preparation of *N*-(4-Bromo-2,6-dimethylphenyl)-5-trimethylammoniumsalicylaldimine Chloride (9c)

4-Bromo-2,6-dimethylaniline (1.003 g, 5.02 mmol) and (3-formyl-4-hydroxyphenyl)trimethylammonium chloride (1.082 g, 5.02 mmol) were dissolved in ethanol (25 mL), and the resulting solution was stirred at reflux for 16 h. The reaction mixture was allowed to cool and concentrated under reduced pressure. The residue was treated with hexanes (15 mL), removed by filtration, and dried under high vacuum to afford **9c** (1.544 g, 3.88 mmol, 77% yield) as a yellow powder. ¹H NMR (CD₃OD) δ : 8.61 (s, 1H), 8.20 (s, 1H), 8.00 (d, *J* = 8.5 Hz, 1H), 7.31 (s, 2H), 7.22 (d, *J* = 8.5 Hz, 1H), 3.70 (s, 9H), 2.18 (s, 6H). ¹³C NMR (CD₃OD) δ : 168.5, 163.0, 148.4, 140.1, 132.2, 131.9, 126.3, 125.6, 120.4, 120.0, 119.3, 58.2, 18.5. HRMS–ESI (*m*/*z*): [M–Cl]⁺ calcd for C₁₈H₂₂BrN₂O, 361.0916; found 361.0906.

Preparation of NHC–Imine Complex 7a

N-(4-Bromo-2,6-dimethylphenyl)-salicylaldimine **9a** (60 mg, 197 μ mol) was dissolved in anhydrous THF (5 mL). Thallium(I) ethoxide (14 µL, 197 µmol) was added to this solution, and the resulting yellow mixture was stirred for 1.5 h. The green complex 8 (114 mg, 158 µmol) was added as a solid, resulting in a rapid color change of the solution from yellow to red. After 1.5 h, the solvent was removed by high vacuum. The residue was dissolved in benzene (5 mL), and the resulting solution was filtered through a glass wool plug to remove the thallium chloride byproduct. The solvent was removed under high vacuum, and pentane (10 mL) was added to the residue to make a slurry. The red solid was removed by filtration, washed with pentane $(3 \times 5 \text{ mL})$, and dried under high vacuum to afford **7a** (101 mg, 121 µmol, 76% yield) as a red powder. Crystals suitable for X-ray diffraction analysis were obtained by layering pentane over a solution of **7a** in benzene. ¹H NMR (CD₂Cl₂) δ : 18.47 (s, 1H), 7.50 (s, 1H), 7.48 (d, J = 8.0 Hz, 2H), 7.34 (t, J = 7.5 Hz, 1H), 7.26 (t, J = 7.7 Hz, 1H), 7.01–6.95 (m, 6H), 6.91 (s, 1H), 6.77 (s, 1H), 6.48 (t, *J* = 7.3 Hz, 1H), 6.40 (s, 1H), 6.36 (s, 1H), 4.14–3.94 (m, 4H), 2.56 (s, 3H), 2.44 (s, 3H), 2.36 (s, 3H), 2.25 (s, 3H), 2.11 (s, 3H), 1.97 (s, 3H), 1.42 (s, 3H), 1.06 (s, 3H). ¹³C NMR (CD₂Cl₂) δ: 298.7, 220.7, 170.3, 167.5, 152.2, 151.7, 140.2, 139.5, 138.2, 137.6, 137.4, 137.0, 136.9, 135.1, 134.3, 132.7, 129.6, 129.4, 128.6, 128.2, 123.8, 119.1, 117.7, 114.0, 51.8, 51.2, 21.1, 21.0, 20.1, 18.8,

18.3, 18.2, 17.9, 17.8. HRMS–ESI (*m*/*z*): [M]⁺ calcd for C₄₃H₄₅BrClN₃ORu, 829.1511; found 829.1517. Anal. Calc. for C₄₃H₄₅BrClN₃ORu: C, 61.76; H, 5.42; N, 5.02. Found: C, 61.70; H, 5.43; N, 4.90.

Preparation of NHC–Imine Complex 7b

Complex **7b** was prepared in 79% yield from **9b** and **8** by using a procedure similar to that for the preparation of **7a**. ¹H NMR (CD₂Cl₂) δ : 18.43 (s, 1H), 8.06 (dd, J = 9.4 Hz, 2.5 Hz, 1H), 8.02 (d, J = 2.5 Hz, 1H), 7.58 (s, 1H), 7.49 (b, 2H), 7.40 (t, J = 7.4 Hz, 1H), 7.07–7.00 (m, 4H), 6.96 (d, J = 9.4 Hz, 1H), 6.93 (s, 1H), 6.76 (s, 1H), 6.42 (s, 1H), 6.37 (s, 1H), 4.17–3.96 (m, 4H), 2.53 (s, 3H), 2.41 (s, 3H), 2.34 (s, 3H), 2.25 (s, 3H), 2.07 (s, 3H), 1.99 (s, 3H), 1.45 (s, 3H), 1.04 (s, 3H). ¹³C NMR (CD₂Cl₂) δ : 297.2, 214.4, 170.2, 163.0, 147.4, 146.0, 135.6, 134.9, 134.4, 134.0, 133.1, 132.4, 131.9, 131.1, 130.6, 129.9, 129.1, 127.5, 125.9, 125.2, 125.1, 125.0, 124.9, 124.8, 123.8, 123.5, 119.6, 113.8, 113.6, 47.2, 46.6, 16.4, 16.3, 15.4, 14.3, 13.7, 13.5, 13.3, 13.1. HRMS–ESI (m/z): [M]⁺ calcd for C₄₃H₄₄BrClN₄O₃Ru, 874.1361; found 874.1324.

Preparation of NHC–Imine Complex 7c

N-(4-Bromo-2,6-dimethylphenyl)-5-trimethylammoniumsalicylaldimine chloride **9c** (71 mg, 180 μ mol) was dissolved in anhydrous DMF (3 mL). Thallium(I) ethoxide (12.7 μ L, 180 µmol) was added to the solution, and the resulting yellow mixture was stirred for 1 h. The green complex 8 (119 mg, 164 μ mol) was added to this mixture as a solution in THF (0.5 mL), resulting in a rapid color change from yellow to red. After 1 h the solvent was removed under high vacuum. The residue was dissolved in CH₂Cl₂ (20 mL), and the resulting solution was filtered to remove the thallium chloride byproduct. Subsequent manipulations were performed under air with reagent-grade solvents. The filtrate was washed twice with deionized water (20 mL) and once with brine (20 mL), and the organic layer was concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (1 mL), and the resulting solution was transferred into pentane (20 mL) to precipitate a red-brown solid. The precipitate was removed by filtration, washed with pentane (10 mL), and dried under high vacuum to yield **7c** (132 mg, 142 µmol, 87% yield) as a red-brown powder. ¹H NMR $(CD_2Cl_2) \delta$: 18.37 (s, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.64 (s, 1H), 7.46–7.59 (m, 3H), 7.38 (t, J = 6.8 Hz, 1H), 7.14 (d, J = 8.7 Hz, 1H), 7.02 (m, 4H), 6.94 (s, 1H), 6.78 (s, 1H), 6.44 (s, 1H), 6.32 (s, 1H), 3.94–4.16 (m, 4H), 3.79 (s, 9H), 2.52 (s, 3H), 2.44 (s, 3H), 2.39 (s, 3H), 2.26 (s, 3H), 2.03 (s, 3H), 1.97 (s, 3H), 1.42 (s, 3H), 1.09 (s, 3H). ¹³C NMR (CD₂Cl₂) δ: 300.7, 219.4, 170.3, 166.9, 152.1, 151.0, 140.3, 139.3, 139.2, 138.5, 137.7, 137.1, 136.7, 134.6, 134.1, 133.7, 132.2, 130.6, 130.5, 129.8, 129.7, 129.4, 129.3, 128.4, 127.6, 126.1, 124.9, 118.3, 118.0, 58.4, 51.8, 51.3, 21.1, 21.0, 20.0, 18.8, 18.3, 18.1, 18.0, 17.9. HRMS-ESI (*m*/*z*): [M–Cl]⁺ calcd for C₄₆H₅₃BrClN₄ORu, 887.2167; found 887.2125.

Preparation of N,N-Di-3-butenyl-2-nitrobenzenesulfonamide (10i)

A procedure from the literature[40] was modified as follows. 2-Nitrobenzenesulfonamide (1.01 g, 5.00 mmol) and 4-bromo-1-butene (4.05 g, 30.0 mmol) were dissolved in acetone (25 mL), and potassium carbonate (1.73 g, 12.5 mmol) was added to this solution. The resulting mixture was stirred for 5 d. After filtration, the reaction mixture was acidified with formic acid until no additional evolution of $CO_2(g)$ was observed, and then concentrated under reduced pressure. The residue was dissolved in EtOAc, washed once with 1 M HCl (50 mL), twice with saturated aqueous NaHCO₃ (50 mL), and once with brine (50 mL). The organic layer was dried with MgSO₄(s) and concentrated under reduced pressure. The crude product was purified by flash chromatography (20% EtOAc v/v in hexane) to afford **10i** (180 mg, 0.580 mmol, 11.6%) as a yellow oil. ¹H NMR (CDCl₃) δ : 8.07–8.01 (m, 1H), 7.72–7.61 (m, 3H), 5.77–5.64 (m, 2H), 5.13–4.98 (m, 4H), 3.39 (t, *J* = 7.6 Hz, 4H), 2.31 (q, *J* = 7.6 Hz, 4H). ¹³C NMR (CDCl₃) δ : 148.2, 134.3, 133.9, 133.6, 131.8, 131.0, 124.3,

117.6, 46.9, 32.8. HRMS–ESI (*m*/*z*): [M+Na]⁺ calcd for C₁₄H₁₈N₂O₄SNa, 333.0885; found 333.0891.

Preparation of N-(2-Propenyl)-N-(2-butynyl)-4-methylbenzenesulfonamide (10j)

Following the procedure of Pagenkopf and coworkers,[39] *N*-(2-propenyl)-4methylbenzenesulfonamide (2.00 g, 9.51 mmol), 1-bromo-2-butyne (3.79 g, 28.5 mmol), and potassium carbonate (1.58 g, 11.41 mmol) yielded **10j** (1.15 g, 4.36 mmol, 46%) as a yellow oil following silica gel flash chromatography (10% EtOAc v/v in hexane). ¹H NMR data were in agreement with those reported by Buchwald and coworkers.[41]

Preparation of Allyl 1,1-Diphenylpropargyl Ether (10k)

Allyl 1,1-diphenylpropargyl ether was prepared by the method of Dixneuf and coworkers. [42] $R_f = 0.52$ (silica gel, 5% EtOAc v/v in hexane). ¹H NMR (CDCl₃) δ : 7.58 (d, J = 7.6 Hz, 4H), 7.30 (t, J = 7.4 Hz, 4H), 7.23 (t, J = 7.2 Hz, 2H), 6.05–5.93 (m, 1H), 5.36 (d, J = 17.5, 1H), 5.16 (d, J = 10.4 Hz, 1H), 4.04 (d, J = 5.1 Hz, 2H), 2.86 (s, 1H). ¹³C NMR (CDCl₃) δ : 143.3, 134.9, 128.4, 127.9, 126.7, 116.3, 83.4, 80.2, 77.8, 66.1. HRMS–ESI (m/z): [M+Na]⁺ calcd for C₁₈H₁₆ONa, 271.1099; found 271.1106.

Representative Procedure for RCM Reactions

On the benchtop under air, the ruthenium complex **7a** (1.6 mg, 1.9 μ mol) was dissolved in non-distilled, non-degassed C₆D₆ (0.75 mL) in an NMR tube, and substrate **10c** (8.1 μ L, 38 μ mol) was added to this solution. The tube was capped, wrapped with parafilm, shaken, and placed in a temperature-controlled water bath at 55 °C. Product formation was monitored by ¹H NMR integration of the allylic methylene signals.

Alternative Preparation of NHC–Imine Complex 7a

A flame-dried Schlenk flask was charged with 1,3-bis(2,4,6-trimethylphenyl)-4,5dihydroimidazolium tetrafluoroborate (12.2 mg, 30.9 μ mol) and anhydrous hexanes (5 mL). After the addition of 1.7 M potassium *t*-amylate in toluene (18.2 μ L, 30.9 μ mol), the suspension was stirred for 5 min. Complex **6a** (5.0 mg, 6.2 μ mol) was added as a solid, and the resulting reddish mixture was heated to 75 °C for 1 h, after which the solvent was removed under high vacuum. The crude product was analyzed by ¹H NMR in CD₂Cl₂.

Structure Determination of NHC–Imine Complex 7a

A red crystal of complex **7a** with approximate dimensions $0.36 \times 0.31 \times 0.30 \text{ mm}^3$ was selected under oil under ambient conditions and attached to the tip of a nylon loop. The crystal was mounted in a stream of cold N₂(g) at 100(2) K and centered in the X-ray beam by using a video camera.

The crystal evaluation and data collection were performed on a Bruker CCD-1000 diffractometer with Mo K_{α} ($\lambda = 0.71073$ Å) radiation and a diffractometer to crystal distance of 4.9 cm.

The initial cell constants were obtained from three series of ω scans at different starting angles. Each series consisted of 20 frames collected at intervals of 0.3° in a 6° range about ω with the exposure time of 15 s per frame. A total of 141 reflections was obtained. The reflections were indexed successfully with an automated indexing routine built in the SMART program. The final cell constants were calculated from a set of 13907 strong reflections from the actual data collection.

Diffraction data were collected by using the hemisphere data collection routine. The reciprocal space was surveyed to the extent of a full sphere to a resolution of 0.80 Å. A total of 27059 data were harvested by collecting three sets of frames with 0.3° scans in ω and ϕ with an exposure time 45 s per frame. These highly redundant datasets were corrected for Lorentz and polarization effects. The absorption correction was based on fitting a function to the empirical transmission surface as sampled by multiple equivalent measurements.[43]

The systematic absences in the diffraction data were consistent for the space groups PI and P1. The *E*-statistics strongly suggested the centrosymmetric space group PI that yielded chemically reasonable and computationally stable results of refinement.[43]

A successful solution by the direct methods provided most non-hydrogen atoms from the *E*-map. The remaining non-hydrogen atoms were located in an alternating series of least-squares cycles and difference Fourier maps. All non-hydrogen atoms were refined with anisotropic displacement coefficients. All hydrogen atoms were included in the structure factor calculation at idealized positions and were allowed to ride on the neighboring atoms with relative isotropic displacement coefficients.

The final least-squares refinement of 459 parameters against 7597 data resulted in residuals R (based on F^2 for $I \ge 2\sigma$) and wR (based on F^2 for all data) of 0.0262 and 0.0739, respectively. The final difference Fourier map was featureless.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to H. E. Blackwell, L. L. Kiessling, D. M. Lynn, and M. Kim for contributive discussions. J.B.B. was supported by an NDSEG Fellowship sponsored by the Air Force Office of Scientific Research. This work was supported by grant GM44783 (NIH). NMRFAM was supported by grant P41RR02301 (NIH).

References

- For reviews, see: a) Grubbs, RH., editor. Handbook of Metathesis. Vol. 1–3. Wiley–VCH; Weinheim, Germany: 2003. b) Nicolaou KC, Bulger PG, Sarlah D. Angew Chem Int Ed 2005;44:4490–4527. c) Grubbs RH. Angew Chem Int Ed 2006;45:3760–3765.
- 2. Schwab P, Grubbs RH, Ziller JW. J Am Chem Soc 1996;118:100-110.
- 3. Kingsbury JS, Harrity JPA, Bonitatebus PJ Jr, Hoveyda AH. J Am Chem Soc 1999;121:791-799.
- 4. Scholl M, Ding S, Lee CW, Grubbs RH. Org Lett 1999;1:953–956. [PubMed: 10823227]
- 5. Garber SB, Kingsbury JS, Gray BL, Hoveyda AH. J Am Chem Soc 2000;122:8168-8179.
- 6. For a recent notable example, see: Bieniek M, Bujok R, Cabaj M, Lugan N, Lavigne G, Arlt D, Grela K. J Am Chem Soc 2006;128:13652–13653. [PubMed: 17044669]
- For examples, see: a) Mortell KH, Gingras M, Kiessling LL. J Am Chem Soc 1994;116:12053– 12054. b) Miller SJ, Blackwell HE, Grubbs RH. J Am Chem Soc 1996;118:9606–9614. c) Kiessling LL, Strong LE. Top Organomet Chem 1998;1:199–231. d) Leeuwenburgh MA, van der Marel GA, Overkleeft HS. Curr Opin Chem Biol 2003;7:757–765. [PubMed: 14644186] e) Agrofoglio LA, Nolan SP. Curr Top Med Chem (Sharjah, United Arab Emirates) 2005;5:1541–1558. f) Gaich T, Mulzer J. Curr Top Med Chem (Sharjah, United Arab Emirates) 2005;5:1473–1494. g) Jenkins CL, Vasbinder MM, Miller SJ, Raines RT. Org Lett 2005;7:2619–2622. [PubMed: 15957905] h) Martin WHC, Blechert S. Curr Top Med Chem (Sharjah, United Arab Emirates) 2005;5:1559–1577. j) Stymiest JL, Mitchell BF, Wong S, Vederas JC. J Org Chem 2005;70:7799–7809. [PubMed: 16277299] k) Van de Weghe P, Eustache J. Curr Top Med Chem (Sharjah, United Arab Emirates) 2005;5:1495–1519.

Page 9

l) Van de Weghe P, Eustache J, Cossy J. Curr Top Med Chem (Sharjah, United Arab Emirates) 2005;5:1461–1472.

- a) Streck R. J Mol Catal 1992;76:359–372. b) Yao Q, Zhang Y. Angew Chem Int Ed 2003;42:3395– 3398.c) Cornils, B.; Herrmann, WA., editors. Aqueous-Phase Organometallic Catalysis. 2. Wiley– VCH; Weinheim, Germany: 2004.
- 9. Hong SH, Grubbs RH. J Am Chem Soc 2006;128:3508-3509. [PubMed: 16536510]
- 10. Mohr B, Lynn DM, Grubbs RH. Organometallics 1996;15:4317–4325.Gallivan JP, Jordan JP, Grubbs RH. Tetrahedron Lett 2005;46:2577–2580.
- 11. Kirkland TA, Lynn DM, Grubbs RH. J Org Chem 1998;63:9904–9909.
- 12. Lynn DM, Mohr B, Grubbs RH, Henling LM, Day MW. J Am Chem Soc 2000;122:6601–6609.
- 13. a) Drozdzak R, Allaert B, Ledoux N, Dragutan I, Dragutan V, Verpoort F. Adv Synth Catal 2005;347:1721–1743. b) Drozdzak R, Allaert B, Ledoux N, Dragutan I, Dragutan V, Verpoort F. Coord Chem Rev 2005;249:3055–3074. c) Drozdzak R, Ledoux N, Allaert B, Dragutan I, Dragutan V, Verpoort F. Cent Eur J Chem 2005;3:404–416.
- 14. De Clercq B, Verpoort F. Adv Synth Catal 2002;344:639–648.
- 15. Chang S, Jones L II, Wang C, Henling LM, Grubbs RH. Organometallics 1998;17:3460-3465.
- 16. De Clercq B, Verpoort F. Tetrahedron Lett 2002;43:9101-9104.
- 17. De Clercq B, Verpoort F. J Organomet Chem 2003;672:11–16.
- 18. Opstal T, Verpoort F. Angew Chem Int Ed 2003;42:2876-2879.
- 19. Huang J, Stevens ED, Nolan SP, Petersen JL. J Am Chem Soc 1999;121:2674-2678.
- 20. Sanford MS, Love JA, Grubbs RH. J Am Chem Soc 2001;123:6543-6554. [PubMed: 11439041]
- 21. Sanford MS, Love JA, Grubbs RH. Organometallics 2001;20:5314–5318.
- 22. a) Conrad JC, Amoroso D, Czechura P, Yap GPA, Fogg DE. Organometallics 2003;22:3634–3636.
 b) Conrad JC, Parnas HH, Snelgrove JL, Fogg DE. J Am Chem Soc 2005;127:11882–11883.
 [PubMed: 16117494] c) Conrad JC, Camm KD, Fogg DE. Inorg Chim Acta 2006;359:1967–1973.
 d) Monfette S, Fogg DE. Organometallics 2006;25:1940–1944.
- 23. Lynn DM, Grubbs RH. J Am Chem Soc 2001;123:3187-3193. [PubMed: 11457052]
- 24. Binder JB, Raines RT. unpublished results.
- 25. Love JA, Sanford MS, Day MW, Grubbs RH. J Am Chem Soc 2003;125:10103–10109. [PubMed: 12914474]
- 26. Hartley FR. Chem Soc Rev 1973;2:163-179.
- 27. Jafarpour L, Hillier AC, Nolan SP. Organometallics 2002;21:442-444.
- 28. a) Allaert B, Dieltiens N, Ledoux N, Vercaemst C, Van Der Voort P, Stevens CV, Linden A, Verpoort F. J Mol Catal A: Chem 2006;260:221–226. b) Ledoux N, Allaert B, Schaubroeck D, Monsaert S, Drozdzak R, Van Der Voort P, Verpoort F. J Organomet Chem 2006;691:5482–5486.
- 29. Lynn, DM. PhD thesis. California Institute of Technology; 1999.
- 30. Walter, F.; De Clercq, B. US Patent App. 2005043541. 2005.
- 31. Connon SJ, Blechert S. Bioorg Med Chem Lett 2002;12:1873–1876. [PubMed: 12086837]
- 32. Hahn FE, Paas M, Froehlich R. J Organomet Chem 2005;690:5816–5821.
- Michrowska A, Gulajski L, Kaczmarska Z, Mennecke K, Kirschning A, Grela K. Green Chem 2006;8:685–688.
- 34. a) Fuerstner A, Thiel OR, Ackermann L, Schanz HJ, Nolan SP. J Org Chem 2000;65:2204–2207. [PubMed: 10774047] b) Furstner A, Ackermann L, Gabor B, Goddard R, Lehmann CW, Mynott R, Stelzer F, Thiel OR. Chem-Eur J 2001;7:3236–3253.
- 35. Sanford MS, Henling LM, Grubbs RH. Organometallics 1998;17:5384–5389.
- 36. a) Cairo CW, Gestwicki JE, Kanai M, Kiessling LL. J Am Chem Soc 2002;124:1615–1619.
 [PubMed: 11853434] b) Gestwicki JE, Cairo CW, Strong LE, Oetjen KA, Kiessling LL. J Am Chem Soc 2002;124:14922–14933. [PubMed: 12475334] c) Kiessling LL, Gestwicki JE, Strong LE. Angew Chem Int Ed 2006;45:2348–2368.
- 37. Ando M, Emoto S. Bull Chem Soc Jpn 1978;51:2433-2434.
- 38. Varray S, Lazaro R, Martinez J, Lamaty F. Organometallics 2003;22:2426-2435.
- 39. Patel MC, Livinghouse T, Pagenkopf BL. Org Synth 2003;80:93–103.

Binder et al.

- 40. Handa S, Kachala MS, Lowe SR. Tetrahedron Lett 2004;45:253-256.
- 41. Sturla SJ, Buchwald SL. J Org Chem 1999:64.
- 42. Le Paih J, Rodriguez DC, Derien S, Dixneuf PH. Synlett 2000:95-97.
- 43. Bruker–AXS. SADABS V.2.05, SAINT V.6.22, SHELXTL V.6.10 & SMART 5.622 Software Reference Manuals. Bruker–AXS; Madison, WI, USA: 2000–2003.
- 44. Wakamatsu H, Blechert S. Angew Chem Int Ed 2002;41:2403–2405.
- 45. Zaja M, Connon SJ, Dunne AM, Rivard M, Buschmann N, Jiricek J, Blechert S. Tetrahedron 2003;59:6545–6558.

Binder et al.




Figure 1. Olefin metathesis catalysts.






Figure 2.

Solid-state molecular structure of complex **7a**. Hydrogen atoms are omitted for clarity. Thermal ellipsoids are shown at 50% probability. Selected bond lengths (Å) and angles (°): Ru–C37 1.838(2), Ru–C16 2.032(2), Ru–C1 2.0530(15), Ru–O 2.1080(18), Ru–N1 2.3976(6), C16–N2 1.347(3), C16–N3 1.346(3), C7–N1 1.301(3), C37–H37 0.9500, C37–C38 1.476(3); C37–Ru–C16 98.28(9), C37–Ru–O 98.70(9), C16–Ru–N1 158.34(8), O–Ru–N1 89.40(6), C37–Ru–C1 88.79(8), C16–Ru–O 83.79(7), C37–Ru–N1 103.07(8), C16–Ru–Cl 94.73(6), O–Ru–Cl 172.50(4), N1–Ru–Cl 89.35(5).

Binder et al.







Synthesis of NHC–imine complexes **7a–c** by the reported route from **6a** [17] and our route from **8**.

Table 1

^1H NMR (CDCl_3) data for 7a and related complexes.

Compound	δ (ppm), Ru=CHAr	δ (ppm), ArCH ₃
7a	18.56 (s, 1H)	2.60 (s, 3H), 2.41 (s, 3H), 2.28 (s, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 2.00 (s, 3H), 1.46 (s, 3H), 1.04 (s, 3H)
7 a [17]	19.42 (s, 1H)	2.49 (s, 6H), 2.31 (s, 3H), 2.20 (s, 6H), 2.09 (s, 3H), 1.76 (s, 3H), 1.72 (d, 3H)
6a [14]	19.45 (d, 1H)	2.45 (q, 3H), 2.33 (s, 3H), 1.78 (d, 3H), 1.71–1.14 (m, 30H)
$1^{[a]}$ [2]	20.02 (s, 1H)	2.62–1.15 (m, 66H)
$2^{[a]}$ [4]	19.16 (s, 1H)	2.56-0.15 (m, 51H)
3 [3]	17.44 (d, 1H)	2.37-1.20 (m, 33H), 1.80 (d, 6H)
4a [5]	16.56 (s, 1H)	2.48 (s, 12H), 2.40 (s, 6H), 1.27 (d, 6H)

[a]_{CD2Cl2}.

NIH-PA Author Manuscript

Binder et al.

Eto2c_co2Et	land,	Complex (mol0/)	Time (h)	Complex (mal02) Time (h) Conversion (02 /b]
Et02C C02Et	COLC. [M])	Compress (mon /0)		
~	CH ₂ Cl ₂ (0.01)	2 (1)	1.5	<i>[5]</i>
	CH ₂ Cl ₂ (0.01)	4c (1)	0.16	<i>[2]</i> 66
11a	C ₆ D ₅ Cl(0.1)	6a (5)	4	100[d]
	$C_6 D_6 (0.1)$	7a (5)	4	100[e]
	$C_6 D_6 (0.1)$	7a (5)	72	90
	$C_7 D_8 (0.05)$	7b (5)	70	76
	CD ₃ OD(0.025)	7b (5)	23	94
	$C_6 D_6 (0.05)$	7c (5)	40	>95
	CD ₃ OD(0.05)	7c (5)	12	>95
211	2:1 CD ₃ OD/D ₂ O (0.025)	7c (10)	9	60

~
~
=
÷
ູບ
\geq
2
Author
Ħ
2
0
_
2
\geq
യ
Manuscrij
Ô
Ξ.
0
¥.

Complex (mol%) Time (h) Conversion $(\%)^{lbl}$ 36 34 29 6 9 6 **7b** (5) **7c** (5) 7c (5) 2:1 CD₃OD/D₂O (0.025) Solvent (Substrate Conc. [M]) CD₃OD(0.025) CD₃OD(0.05) Product F₃C₀] []


Binder et al.

Adv Synth Catal. Author manuscript; available in PMC 2010 July 23.

7
\leq
=
-
U
\geq
\geq
-
⊢
utho
ō
≚
~
ň
uscri
0
Ξ.
¥.

	Product	Solvent (Substrate Conc. [M])	Complex (mol%)	Time (h)	Complex (mol%) Time (h) Conversion (%)[b]
		CH ₂ Cl ₂ (0.01)	4 a (1)	4.5	91 <i>[f]</i>
	, ⊥	C ₆ D ₆ (0.05)	7a (5)	9	8
		C ₆ D ₆ (0.05)	7a (5)	26	68
		$C_6 D_6 (0.05)$	7b (5)	24	10
ł	_	$C_7 D_8 (0.05)$	7b (5)	9	43 (+ 8) <i>[8]</i>
C Adv		$C_7 D_8 (0.05)$	7b (5)	70	92
D v Sym	2	CD ₃ OD(0.025)	7b (5)	6	>95
th C		$C_6 D_6 (0.05)$	7c (5)	9	7
atal.		CD ₃ OD(0.05)	7c (5)	9	>95
Auth	_	2:1 CD ₃ OD/D ₂ O (0.025)	7c (5)	9	93
or manu					
iscript:	ĺ				
availat					
De in F					
PMC 20					
)10 July	/ 10-				

Binder et al.



Binder et al.

~
~
_
<u> </u>
~
-
-
uthor
<u> </u>
+
-
0
_
_
\leq
_
0
1
lan
_
-
<u> </u>
10
0)
0
0
-
uscrip
-
0
<u> </u>

[4]\
×
•

Binder et al.

Complex (mol%) Time (h) Conversion $(\%)^{[b]}$ 79 40 12 6 **7c** (5) **7c** (10) 2:1 CD₃OD/D₂O (0.025) Solvent (Substrate Conc. [M]) CD₃OD(0.05) Product N[†]CI^{\$} 11e

Adv Synth Catal. Author manuscript; available in PMC 2010 July 23.

7
\leq
T
- T
Τ
\geq
-
4
5
÷
ō
uthor
_
2
P
2
5
Manuscrij
<u>۲.</u>
5
4

Product	Solvent (Substrate Conc. [M])		Time (h)	Complex (mol%) Time (h) Conversion (%) bJ
ó	$C_7 D_8 (0.05)$	7b (5)	40	45
	CD ₃ OD(0.025)	7b (5)	6	94
III	$C_6 D_6 (0.05)$	7c (5)	40	65
	CD ₃ OD(0.05)	7c (5)	6	>95
	2:1 CD ₃ OD/D ₂ O (0.025)	7c (5)	9	57

Binder et al.

Complex (mol%) Time (h) Conversion $(\%)^{[b]}$	10 <5 <5	
Time (h)	6 6 6	
Complex (mol%)	7b (5) 7c (5) 7c (5)	
Solvent (Substrate Conc. [M])	C ₇ D ₈ (0.05) C ₆ D ₆ (0.05) CD ₃ OD(0.05)	
Product		2010 July 23.

Binder et al.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

67

11g

Complex (mol%) Time (h) Conversion (%)[b]

Solvent (Substrate Conc. [M])

Binder et al.

Product

Z Ţ
+-P/
A
Author
Z
lanu
uscri
ipt

nuscript NIH-PA Author Manuscript

Product Conc. [M] Complex (mol%) Time (h) Conversion (%) ^{b1} IIh $C_{7B}(0.65)$ $7a$ (s) 40 95 Cb $C_{7B}(0.05)$ $7h$ (s) 40 95 Cb $C_{9B}(0.05)$ $7h$ (s) 40 95 Cb $C_{9B}(0.05)$ $7h$ (s) 40 95 Cb $C_{9B}(0.05)$ $7h$ (s) 7 95 Cb $C_{9D}(0.025)$ $7h$ (s) 7 95 Cb $C_{9D}(0.025)$ $7h$ (s) 7 95 Cb $2000(0.05)$ $7e$ (s) 7 95	Solvent (Su)				1
$ \left. \left. \begin{array}{cccc} C_7 D_8 \left(0.05 \right) & \mbox{7a} \left(5 \right) & \mbox{40} \\ C_7 D_8 \left(0.05 \right) & \mbox{7b} \left(5 \right) & \mbox{40} \\ C D_3 OD \left(0.025 \right) & \mbox{7b} \left(5 \right) & \mbox{5} \\ C D_3 OD \left(0.05 \right) & \mbox{7c} \left(5 \right) & \mbox{7} \\ C D_3 OD \left(0.05 \right) & \mbox{7c} \left(5 \right) & \mbox{7} \\ 2:1 C D_3 OD \left(0.025 \right) & \mbox{7c} \left(5 \right) & \mbox{6} \\ \end{array} \right. $			Complex (mol%)	Time (h)	Conversion (%) ^[b]
$\begin{array}{cccc} C_{7}D_8 \left(0.05 \right) & \mbox{7b} \left(5 \right) & \mbox{40} \\ CD_3 OD \left(0.025 \right) & \mbox{7b} \left(5 \right) & \mbox{5} \\ C_6 D_6 \left(0.05 \right) & \mbox{7c} \left(5 \right) & \mbox{7} \\ CD_3 OD \left(0.05 \right) & \mbox{7c} \left(5 \right) & \mbox{7} \\ 2:1 CD_3 OD /D_2 O \left(0.025 \right) & \mbox{7c} \left(5 \right) & \mbox{6} \\ \end{array} \right)$	C ₇ D ₈ (0.	(0.05)	7a (5)	40	>95
$CD_{3}OD(0.025) \qquad 7b (5) \qquad 5 \\ C_{6}D_{6} (0.05) \qquad 7c (5) \qquad 40 \\ CD_{3}OD(0.05) \qquad 7c (5) \qquad 7 \\ 2.1 CD_{3}OD/D_{2}O (0.025) \qquad 7c (5) \qquad 6 \\ \end{array}$		(0.05)	7b (5)	40	>95
7c (5) 40 7c (5) 7 7c (5) 6		0(0.025)	7b (5)	5	95
7c (5) 7 7c (5) 6	C ₆ D ₆ (0.	(0.05)	7c (5)	40	>95
7c (5) 6	CD ₃ OD(C	D(0.05)	7c (5)	7	>95
	2:1 CD ₃ OD/D ₂	/D ₂ O (0.025)	7c (5)	9	85

Binder et al.

Adv Synth Catal. Author manuscript; available in PMC 2010 July 23.

Binder et al.

Complex (mol%) Time (h) Conversion (%)[b] Solvent (Substrate Conc. [M]) Product

Product	Solvent (Substrate Conc. [M])	Complex (mol%)	Time (h)	Conversion $(\%)^{[b]}$
	$C_7D_8 (0.05)$	7a (5)	40	06
<	C ₇ D ₈ (0.05)	7b (5)	40	06
	CD ₃ OD(0.025)	7b (5)	6	93
	C ₆ D ₆ (0.05)	7c (5)	40	89
	CD ₃ OD(0.05)	7c (5)	7	>95
	2:1 CD ₃ OD/D ₂ O (0.025)	7c (10)	6	>95
n PMC 2				
_				
Ì				
11				

Adv Synth Catal. Author manuscript, available in PMC 2010 July 23.

Binder et al.

NIH-PA Author Manuscript

Complex (mol%) Time (h) Conversion (%)[b]

Solvent (Substrate Conc. [M])

Product

Binder et al.

Product	Solvent (Substrate Conc. [M])	Complex (mol%) Time (h)	Time (h)	Conversion (%)[b]
	$C_7 D_8 (0.05)$	7a (5)	36	7
ł	$C_7 D_8 (0.05)$	7b (5)	36	7
	CD ₃ OD(0.025)	7b (5)	36	25
	$C_6 D_6 (0.05)$	7c (5)	36	42
	CD ₃ OD(0.05)	7c (5)	36	32
-z				

Adv Synth Catal. Author manuscript; available in PMC 2010 July 23.

Binder et al.

NIH-PA Author Manuscript

11j

	1	
\mathbf{Z}		
Ŧ		
<u></u>		
4		
5		
P		
Ŧ		
2		
Ÿ		
<		
a		
VIH-PA Author Manuscrip		
õ		
-Fi		
¥		

Product	Solvent (Substrate Conc. [M])	Complex (mol%)	Time (h)	Complex (mol%) Time (h) Conversion (%) bJ
, Ph	C ₇ D ₈ (0.05)	7a (5)	36	93
Ha ha	$C_7 D_8 (0.05)$	7b (5)	18	>95
	CD ₃ OD(0.025)	7b (5)	2	06
llk	C ₆ D ₆ (0.05)	7c (5)	S	>95
	CD ₃ OD(0.05)	7c (5)	2	>95
	5:2 CD ₃ OD/D ₂ O (0.02)	7c (10)	9	>95
	5:2 CH ₃ OH/H ₂ O (0.02)	4d (5)	0.5	92[i]

Table 3

Solvent dependence of RCM of *N*-tosyl diallylamine (10c) catalyzed by complex 7b.^[a]

Solvent	Dielectric constant (ɛ)	Conversion (%)
C_6D_6	2.28	14
CD_2Cl_2	8.9	36
CD ₃ OD	32.6	69

 ${\it [a]}_{\rm Reaction}$ conditions: 5 mol% **7b**, 0.025 M substrate **10c**, 40 °C, 24 h, under air.